No Data
No Data
Thalys Medical Technology to Divest Subsidiary for 31 Million Yuan
Thalys Medical Technology Group Corporation (603716.SH): Intends to transfer 51% equity of Aksu Yonglin.
On September 5th, Thalys Medical Technology Group Corporation (603716.SH) announced that, in order to further optimize the company's business operation structure and improve the efficiency of asset operation and utilization, the company plans to sign an "equity transfer agreement" with Rongda Zhiyuan II, agreeing to transfer the company's 51% equity stake in Aksu Yongyang Lin to Rongda Zhiyuan II for a consideration of 31 million yuan. After the completion of this equity transfer, Aksu Yongyang Lin will no longer be a subsidiary controlled by the company and will no longer be included in the company's consolidated financial statements. During the period when Aksu Yongyang Lin was a subsidiary controlled by the company, the company provided loans to support its daily operation, as of 2024.
Thalys Medical Technology Group Corporation (603716.SH): has cumulatively repurchased 0.9475% of the shares.
Thalys Medical Technology Group Corporation (603716.SH) announced that as of September 3, 2024, the company's share repurchase program has been completed. The company has repurchased a total of 1,907,700 shares through centralized auction trading, accounting for 0.9475% of the company's current total share capital. The highest price for the repurchase transaction was 6.02 yuan/share, the lowest price was 5.54 yuan/share, and the average repurchase price was 5.79 yuan/share. The total amount paid for the repurchase was 11,053,889 yuan (excluding transaction fees).
2024 Semi-Annual Report Summary
2024 Semi-Annual Report
Thalys Medical Technology Group Corporation (603716.SH): net loss of 4,772.5 million yuan in the first half of the year.
Thalys Medical Technology Group Corporation (603716.SH) announced on August 29th that the company achieved a total operating revenue of 0.976 billion yuan in the first half of 2024, a year-on-year decrease of 3.48%. The net income attributable to the shareholders of the parent company was -4.7725 million yuan, compared to a net income of 1.5306 million yuan in the same period last year. The basic earnings per share were -0.02 yuan.
No Data
No Data